GSK-205017

Study Sponsor: GSK

Study Title

A three part, non-randomised, open label study designed to assess the pharmacokinetics of GSK2982772 following administration of minitab modified release formulations in a capsule relative to an immediate release reference tablet formulation (Part A), the pharmacokinetics of escalating, repeat doses of a selected minitab modified release prototype (Part B), and the pharmacokinetics of GSK2982772 following administration of modified release tablet formulations in the fed and fasted state (Part C) in healthy participants

Medicine or Vaccine (generic name)

GSK2982772

Sponsor Identification Number

205017

Trial Registry Identification Number(#'s)

NCT03266172

Medical Condition

Autoimmune Diseases

Phase

Phase 1

Link to study details on the GSK Clinical Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=205017

Link to study details on ClinicalTrials.gov (if available)

https://www.clinicaltrials.gov/ct2/show/NCT03266172

Link to study details on EudraCT (if available)

https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2017-000652-25

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

Date Added to this Site

July 2021